Svoz Ophthalmic Solution Mechanism of Action

Pharmacology: Pharmacodynamics: Moxifloxacin is a Fluoroquinolone anti-infective agent. Like other commercially available fluoroquinolones, Moxifloxacin contains a fluorine at the C-6 position of the quinolone nucleus. Moxifloxacin, like gatifloxacin, contains an 8-methoxy group and has been termed an 8-methoxy fluoroquinolone. Moxifloxacin inhibits DNA synthesis in susceptible organisms via inhibition of type II topoisomerases (DNA gyrase and topoisomerase IV). DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA.
Pharmacokinetics: Following topical application to both eyes of Moxifloxacin 0.5% ophthalmic solution 3 times daily for 5 days in healthy adults, mean steady-state peak, plasma concentrations and estimated daily exposure, as determined by area under the plasma concentration-time curve (AUC), reportedly were 1600 and 1000 times lower, respectively, than values attained following oral administration of therapeutic (400 mg daily for 10 days) doses of the drug.